Details of the Drug Reposition

General Information of This Drug (ID: DM7RJXL)

Drug Name
Imatinib   DM7RJXL
Synonyms
Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
10 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Malignant peripheral nerve sheath tumor DIS0JTN6 N.A. Approved [1]
Leukemia DISNAKFL N.A. Approved [1]
Dermatofibrosarcoma protuberans DIS4OCQM N.A. Approved [1]
Chronic eosinophilic leukemia DISAJOUO N.A. Approved [1]
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive DIS3KLUX N.A. Approved [1]
Myeloproliferative neoplasm DIS5KAPA 2A20 Approved [1]
Gastrointestinal stromal tumour DIS6TJYS 2B5B Approved [1]
Choroidal neovascularization DISLGVL7 9B76 Approved [1]
Pulmonary hypertension DIS1RSP5 BB01 Approved [1]
Acute lymphoblastic leukaemia DIS87TGM 2A85 Approved [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Indications(s)
2 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 3 [3]
Intestinal cancer DISYCNF1 2C0Z Phase 3 [4]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Lung cancer DISCM4YA 2C25.0 Phase 2 [4]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Systemic mastocytosis DISNQ2OY 2A21.0 Discontinued in Phase 3 [5]
------------------------------------------------------------------------------------
2 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Leukemia, myeloid, accelerated-phase DISNDQL5 N.A. Discontinued in Phase 1 [6]
Metastatic melanoma DISSL43L 2E2Z Discontinued in Phase 1 [7]
------------------------------------------------------------------------------------
4 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Idiopathic hypereosinophilic syndrome DISXAPO9 N.A. Investigative [1]
Middle East Respiratory Syndrome (MERS) DIS5VPYU 1D64 Investigative [8]
Severe acute respiratory syndrome (SARS) DISYW14W 1D65 Investigative [8]
Scleroderma DISVQ342 4A42 Investigative [1]
------------------------------------------------------------------------------------

References

1 Imatinib FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 ClinicalTrials.gov (NCT04356495) Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19). U.S. National Institutes of Health.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687).
5 A Study of Abatacept in Patients With Active Crohn's Disease
6 ClinicalTrials.gov (NCT00560352) Safety Study of Dasatinib With Bortezomib (Velcade) and Dexamethasone for Multiple Myeloma
7 Safety, Tolerability & Pharmacokinetics (PK) of Co-administered Single Doses of OZ439 and Mefloquine (MQ) in Healthy Volunteers
8 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.